Joseph, Susan M.

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: A multicenter randomized trial

Nassif, M. E., Windsor, S. L., Borlaug, B. A., Kitzman, D. W., Shah, S. J., Tang, F., Khariton, Y., Malik, A. O., Khumri, T., Umpierrez, G., et al. (2021) · Nature Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 618

Cardiovascular Phenotype in HFpEF Patients With or Without Diabetes

Lindman, B. R., Dávila-Román, V. G., Mann, D. L., McNulty, S., Semigran, M. J., Lewis, G. D., de las Fuentes, L., Joseph, S. M., Vader, J., Hernandez, A. F., et al. (2014) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 209

Comparable Performance of the Kansas City Cardiomyopathy Questionnaire in Patients With Heart Failure With Preserved and Reduced Ejection Fraction

Joseph, S. M., Novak, E., Arnold, S. V., Jones, P. G., Khattak, H., Platts, A. E., Dávila-Román, V. G., Mann, D. L., & Spertus, J. A. (2013) · Circulation: Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 192

Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy

Docherty, K. F., Jhund, P. S., Bengtsson, O., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Sabatine, M. S., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 44